Paper · 35584326

Targeting syndecan-1: new opportunities in cancer therapy.

Yang Z and 3 others. Am J Physiol Cell Physiol, 2022. Cited by 45 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Targeting syndecan-1: new opportunities in cancer therapy. Papers, record 35584326. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35584326

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Targeting syndecan-1: new opportunities in cancer therapy.; PubMed
Journal: Am J Physiol Cell Physiol; PubMed
Year: 2022; PubMed
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/35584326/; PubMed
DOI: https://doi.org/10.1152/ajpcell.00024.2022; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9236862/; PubMed
The journal: https://conductscience.org/library/journal-index/100901225; PubMed
Citations, by iCite: 45; iCite
Relative citation ratio, by iCite: 3.5; iCite
Revised in PubMed: 2024-09-29; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Yang Z	Zecheng	https://orcid.org/0000-0001-5325-6809
2	Chen S	Shuaitong
3	Ying H	Haoqiang
4	Yao W	Wantong	https://orcid.org/0000-0002-0172-7530

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Neoplasms	Major topic
Syndecan-1	Major topic
Carcinogenesis
Cell Transformation, Neoplastic
Humans
Signal Transduction

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P01 CA117969	NCI NIH HHS	United States	P01CA117969	PubMed	NIH RePORTER
R01 CA214793	NCI NIH HHS	United States	R01CA214793	PubMed	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References165

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	32,313,833	PDZ Domains as Drug Targets.	Adv Ther (Weinh)	2019	https://conductscience.org/library/papers/32313833	PubMed
2	24,045,542	Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer.	Am J Clin Pathol	2013	https://conductscience.org/library/papers/24045542	PubMed
3	7,508,860	Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein.	EMBO J	1994	https://conductscience.org/library/papers/7508860	PubMed
4	12,860,416	Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain.	FEBS Lett	2003	https://conductscience.org/library/papers/12860416	PubMed
5	9,391,086	Syntenin, a PDZ protein that binds syndecan cytoplasmic domains.	Proc Natl Acad Sci U S A	1997	https://conductscience.org/library/papers/9391086	PubMed
6	34,594,327	Characterization of Organ-Specific Regulatory B Cells Using Single-Cell RNA Sequencing.	Front Immunol	2021	https://conductscience.org/library/papers/34594327	PubMed
7	30,128,502	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.	JAMA Oncol	2018	https://conductscience.org/library/papers/30128502	PubMed
8	19,802,384	Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells.	PLoS One	2009	https://conductscience.org/library/papers/19802384	PubMed
9	27,383,370	Minireview: Syndecans and their crucial roles during tissue regeneration.	FEBS Lett	2016	https://conductscience.org/library/papers/27383370	PubMed
10	22,203,420	Function of the syndecan-4 cytoplasmic domain in oligomerization and association with α-actinin in turkey muscle satellite cells.	Mol Cell Biochem	2012	https://conductscience.org/library/papers/22203420	PubMed

1 to 10 of 165

See all 165 references

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.

PMID	Title	Journal	Year	In Papers	Source
42,935,705	Integrative genomics and experimental validation identify a mechanosensitive gene signature associated with colorectal cancer liver metastasis.	iScience	2026	https://conductscience.org/library/papers/42935705	PubMed
42,738,352	Proteoglycans as Regulators of Receptor Trafficking and Spatial Signaling in Cancer.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42738352	PubMed
42,374,606	SDC1 Knockdown Suppresses Malignant Phenotypes of Breast Cancer by Modulating the MAPK Signaling Pathway.	Cancer Med	2026	https://conductscience.org/library/papers/42374606	PubMed
42,135,859	Identification and validation of lactylation-related genes signature and immune infiltration landscape of rheumatoid arthritis based on machine learning.	Hereditas	2026	https://conductscience.org/library/papers/42135859	PubMed
42,098,527	Integrated pan-cancer analysis and experimental validation reveal that syndecan-1 drives glioblastoma pathogenesis and associates with immune infiltration.	Discov Oncol	2026	https://conductscience.org/library/papers/42098527	PubMed
41,867,770	Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer.	bioRxiv	2026	https://conductscience.org/library/papers/41867770	PubMed
41,866,470	Characterization of KLK5-high epithelial cells and their interactions with the tumor microenvironment in high-grade serous ovarian cancer.	Cancer Cell Int	2026	https://conductscience.org/library/papers/41866470	PubMed
41,836,417	Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1+TAMs in immunotherapy response in non-small cell lung cancer.	Front Immunol	2026	https://conductscience.org/library/papers/41836417	PubMed
41,707,651	Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer.	Cell Rep Med	2026	https://conductscience.org/library/papers/41707651	PubMed
41,570,990	Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles.	J Biol Chem	2026	https://conductscience.org/library/papers/41570990	PubMed

1 to 10 of 33

See all 33 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
SDC1	6,382	PubTator's text mining	https://conductscience.org/library/genes/6382

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35584326

GET https://conductscience.org/api/papers/v1/35584326/references?page=2

API reference For AI assistants